196 results on '"Bengala, C."'
Search Results
2. EE362 A Budget Impact Analysis of Pertuzumab, Trastuzumab, and Chemotherapy in the Neoadjuvant Setting for HER2-Positive High-Risk Early Breast Cancer Patients: Insights from the Tuscany Regional Health Care System Perspective
3. Oropharyngeal squamous cell carcinoma and HPV. Systematic review on overall management
4. C8 INSTITUTIONAL VALIDATION OF THE JOINT ANMCO AND AIOM TUSCANY CLINICAL CARDIO–ONCOLOGY PATHWAY FOR THE CARDIOLOGY MANAGEMENT OF CANCER OUTPATIENTS
5. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study
6. 216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)
7. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer
8. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry
9. Frequenza ed effetti dell'infezione de SARS-CoV-2 in pazienti oncologici
10. Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
11. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
12. Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer pati
13. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
14. High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)
15. HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support
16. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine–epirubicin–paclitaxel in metastatic breast cancer: a dose finding study
17. High-dose chemotherapy and autologous haematopoietic stem cell transplantation as adjuvant treatment in early stage and operable breast cancer: retrospective long-term analysis of the European experience: O433
18. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial
19. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
20. High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)
21. HIGH-DOSE ONDANSETRON (OND) AND DEXAMETASONE (DEX) TO PREVENT ACUTE AND DELAYED EMESIS IN PATIENTS (PTS) RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HAEMOPOIETIC SUPPORT (AHS).
22. Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial
23. P1.15-01 Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience
24. MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients
25. Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients
26. Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial
27. 1318P - Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients
28. LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB
29. DOSE AND OUTCOME. THE HURDLE OF NEUTROPENIA
30. Adjuvant gemcitabine and concurrent radiotherapy in operable patients with advanced pancreatic adenocarcinoma: a phase II study
31. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
32. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
33. Evaluation of thrombopoiesis kinetics by measurement of reticulated platelets and CD34(+) cell subsets in patients with solid tumors following high dose chemotherapy and autologous peripheral blood progenitor cell support
34. Rischio neoplastico post-trapianto
35. Terapia del carcinoma ovarico. B. Terapia medica
36. Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors
37. Measurement of reticulated platelets following high dose chemotherapy with peripheral blood progenitor cell support in patients with solid tumors
38. Mobilization, collection and characterization of peripheral blood hemopoietic progenitors after Epirubicin, Paclitaxel and Granulocyte-colony stimulating factor (G.CSF) in patients with metastatic breast cancer
39. MOBILIZATION, COLLECTION AND CHARACTERIZATION OF PERIPHERAL BLOOD HEMOPOIETIC PROGENITORS AFTER CHEMIOTERAPY WITH EPIRUBICIN, PACLITAXEL AND GRANULOCYTE-COLONY STIMULATING FACTOR ADMINISTERED TO PATIENTS WITH METASTATIC CARCINOMA
40. Crescita tumorale e cinetica cellulare
41. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
42. 7100 High-dose sequential chemotherapy versus conventional-dose chemotherapy as first-line treatment for advanced poor prognosis germ-cell tumors: a multicenter Phase III Italian trial
43. EGFR gene copy number, KRAS and BRAF status, PTEN and AKT expression analysis in patients with metastatic colon cancer treated with anti-EGFR monoclonal antibodies ± chemotherapy
44. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.
45. Predictive value of EGFR gene copy number and K-ras mutation for pathological response to preoperative cetuximab, 5FU, and radiation therapy in locally advanced rectal cancer (LARC)
46. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry
47. Epidoxorubicina ad alte dosi e lonidamina (L) come trattamento di seconda linea nel carcinoma (Ca) ovarico avanzato
48. Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis
49. Treatment of metastatic disease after current adjuvant approaches (taxanes, aromatase inhibitors, trastuzumab)
50. Cardiac tolerability of trastuzumab in metastatic breast cancer (MBC) patients previously treated with high-dose chemotherapy (HDC) with autologous hemopoietic support: Retrospective analysis from Gruppo Italiano Trapianto Midollo Osseo (GITMO) Solid Tumor Working Party
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.